Introduction
============

Phytocannabinoid use in management of multiple sclerosis (MS) symptoms ([@B22]) has led to clinical trial evidence for the efficacy of tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex) in controlling spasticity and pain ([@B126]; [@B40]). MS, a demyelinating disease characterized by persistent neuroinflammation and progressive central nervous system (CNS) demyelination ([@B64]), is only one of many demyelinating neurodegenerative diseases involving oligodendrocytes, the myelinating cells of the CNS. The endocannabinoid system (ECS) ([@B54]; [@B93]) involvement in neuroprotection ([@B91]; [@B123]; [@B73]; [@B105]) and the immune system in CNS diseases ([@B23]; [@B99]; [@B20]; [@B90]) have been reviewed. Here, we address ECS effects on oligodendrocytes and their precursors, in order to evaluate the evolving research around cannabinoids in healthy development and in demyelinating neurodegenerative diseases.

Cannabinoids, Oligodendrocyte Precursor Cells and Oligodendrocytes in Health
============================================================================

Oligodendrocytes, myelinating cells of the vertebrate CNS, enable neurons to signal more energy-efficiently and at higher speed due to saltatory conduction, and maintain axonal integrity through trophic and metabolic support ([@B81]; [@B110]). Generation of oligodendrocytes is an ongoing process, starting in embryonic development and continuing throughout life ([@B11]; [@B121]; [@B30]; [@B81]). In brief, oligodendrocyte precursor cells (OPCs), also known as NG2-glia, O-2A progenitors, polydendrocytes, or synantocytes, arise from neural stem cells (NSCs), and preferentially populate distinct areas of the developing CNS in lineage- and time-specific waves ([@B98]). Upon arrival, many undergo apoptosis, while many others either mature into myelinating oligodendrocytes or persist as progenitors and remain capable of self-renewal as well as production of mature oligodendrocytes well into adulthood ([@B25]). These progenitors become distributed throughout gray and white matter and maintain their respective domains by continuously sampling their environment, able to expand to neighboring areas vacated by other OPCs ([@B62]; [@B56]).

Despite this interchangeability, it is becoming increasingly clear that oligodendrocyte precursors represent a heterogeneous group, distinct in their origin, signaling, and ability to revert differentiation to produce neurons and astrocytes ([@B121]; [@B30]; [@B89]; [@B125]). Regardless of the differences, all OPCs rely on the processes of proliferation, migration, and differentiation to become mature, functioning oligodendrocytes ([@B11]; [@B84]; [@B32]; [@B104]). As these steps are differentially regulated ([@B69]), it is important to look at the effects of cannabinoid agonists on each (see Figure [1](#F1){ref-type="fig"}).
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Survival
--------

Reports of cannabinoid receptors in newborn rat white matter by immunostaining ([@B13]), led to subsequent studies exploring cells *in vitro*. OPCs were isolated from newborn Wistar rat forebrains and expanded by incubation in serum-free defined media with supplements including platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) ([@B86]). OPCs could be differentiated into myelin basic protein (MBP)-producing mature oligodendrocytes by incubation in serum-free defined media in which PDGF and FGF were replaced by triiodothyronine (T3). As ascertained by RT-PCR, Western blot, and immunohistochemistry, both OPC and mature oligodendrocytes expressed both CB~1~ and CB~2~ cannabinoid receptors ([@B86]). Because activation of cannabinoid receptors confers neuroprotection ([@B123]; [@B73]; [@B105]), the influence of cannabinoid agonists on viability of OPCs was investigated. Upon incubation in serum-free DMEM/F12 media for 12 h, nearly half of OPCs underwent apoptosis ([@B86]). However, most were rescued by concurrent supplementation with CB~1~ agonist arachidonyl-2′-chloroethylamide (ACEA, 25 nM) or CB~1~/CB~2~ agonists WIN55212-2 (25 nM) or HU210 (500 nM). Co-treatment with CB~1~ antagonist SR141716 (1 μM) abolished the anti-apoptotic effect of ACEA, but not of WIN55212-2 or HU210. Both SR141716 plus CB~2~ antagonist SR144528 (1 μM) were required to nullify the pro-survival effect of HU210. These results show that the activation of either CB~1~ or CB~2~ receptors could be sufficient in promoting OPC survival under conditions of trophic factor deprivation. The mechanism includes activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, a known modulator of OPC survival ([@B124]; [@B33]). Applying each of the three agonists correlated with increased Akt phosphorylation, while co-treatment with PI3K inhibitors LY294002 (10 μM) or wortmannin (100 nM) nullified the effects of WIN55212-2 and HU210 on both Akt phosphorylation and cell survival ([@B86]). Thus, stimulation of Akt/PI3K pathways via CB~1~ and CB~2~ receptors present in OPCs can curtail apoptotic processes and promote survival.

Proliferation
-------------

Molina-Holgado and colleagues explored the ability of the endocannabinoid system to modulate OPC proliferation and self-renewal ([@B44]). In cultured OPCs ([@B86]), 24-h blockade of CB~1~ receptors with AM281 (1 μM), CB~2~ receptors with AM630 (1 μM), or synthesis of 2-arachidonoylglycerol (2-AG) by diacylglycerol lipase α and β (DAGLs) with RHC80267 (5 μM), led to reduction in PDGF/FGF-stimulated OPC proliferation. In the absence of PDGF and FGF, OPC proliferation increased in response to 24-h application of CB~1~ agonist ACEA (0.5 μM), CB~2~ agonist JWH133 (0.5 μM), 2-AG (1 μM), or JZL184 (1 μM) which blocks the 2-AG metabolizing enzyme monoacylglycerol lipase (MAGL). The effect depended on phosphorylation of Akt and mammalian target of rapamycin (mTOR), as their blockers LY294002 (5 μM) and rapamycin (3 nM), respectively (24 h), decreased the proliferative effects of ACEA, JWH133, and JZL184. Extracellular signal regulated-kinase (ERK) 1/2 phosphorylation was decreased in cells treated with the 2-AG synthesis inhibitor RHC80267, as well as with CB~1~ and CB~2~ antagonists AM281 and AM630, respectively. These results extend the impact of cannabinoid receptor activation from promoting OPC survival ([@B86]) to increasing proliferation, while also implicating cannabinoid-mediated Akt/mTOR and ERK pathways, known to play a role throughout OPC development to myelination ([@B47]; [@B37]).

Migration
---------

NSCs of postnatal subventricular zone (SVZ) emigrate the neurogenic niche in the form of neuroblasts or OPCs ([@B71]). In rat CNS, both myelination and SVZ gliogenesis peak at postnatal day (PD) 15 ([@B14]; [@B50]), making this an optimal time-point for exploring cannabinoid effects on OPC proliferation and migration from postnatal SVZ. Immunohistochemical analysis of PD7 and PD15 Wistar rat brain revealed that the CB~1~ receptor was primarily expressed by radial glia ([@B4]), which can transform to NSCs ([@B80]). However, the CB~2~ receptor co-stained with poly-sialylated neural cell adhesion molecule (PSA-NCAM) ([@B4]), a marker of migration in OPCs and neuroblasts ([@B31]; [@B79]). The CB~1~ agonist ACEA (escalating dose 1.25--2.5 mg/kg, SC daily PD1 to PD14) increased PD15 SVZ staining for 4A4, a marker of radial glia proliferation ([@B53]), and Olig2 ([@B4]), which is expressed in glial precursors fated to become oligodendrocytes ([@B85]). Similar treatment with CB~2~ agonist JWH056 (escalating dose 2.5--5.0 mg/kg, SC) increased SVZ staining for PSA-NCAM. Activation of both CB~1~ and CB~2~ receptors by WIN55212-2 (escalating dose 2.5--5.0 mg/kg, SC) increased MBP staining in the external capsule, which was inhibited below control values by concurrent administration of either SR141716 (CB~1~) or SR144528 (CB~2~) antagonists (escalating dose 2--4 mg/kg, SC) ([@B4]). These results support the involvement of CB~1~ receptors in radial glia proliferation and conversion to oligodendrocytes, but CB~2~ receptors in OPC migration, leading to functional oligodendrocytes in neonatal myelination.

Studies have examined cannabinoid agonist impact on rodent SVZ proliferation beyond the newborn stage. In juvenile (PD35-PD48) Lewis rats, WIN55212-2 (2 mg/kg, IP bid, 2-weeks) increased SVZ BrdU staining, without changing the ratio of progenitors committed to neuronal or OPC fates, or the number of cells undergoing caspase-3 mediated apoptosis ([@B16]). These results are consistent with findings that genetic ablation of CB~1~ receptors decreased progenitor proliferation in adult mouse SVZ ([@B59]; [@B61]). In adult mice, cannabidiol (CBD; 3 mg/kg IP daily for 14 days) increased SVZ proliferative markers Ki67 and BrdU staining ([@B106]). However, CBD at 30 mg/kg decreased proliferation markers ([@B106]), highlighting the importance of dose.

Differentiation to Mature Oligodendrocytes
------------------------------------------

[@B86] investigated OPC differentiation using isolated OPCs differentiated with T3 (30 ng/mL, 48 h) in the absence of PDGF/FGF ([@B45]). Activating either cannabinoid receptor (ACEA for CB~1~ and JWH133 for CB~2~, 0.5 μM) increased OPC branching and accumulation of MBP (Western blot). The CB~1~/CB~2~ agonist HU210 (0.5 μM) evoked the same responses, which could be abolished by either AM281 (CB~1~) or AM630 (CB~2~; 1 μM). The mechanism for HU210-mediated OPC arborization and production of MBP involved PI3K/Akt and mTOR pathways, as these effects were blocked with LY290042 (2.5 μM) and rapamycin (0.75 nM), respectively. [@B43] found the Western blot level of DAGLs to be higher in OPCs, whereas the level of MAGL was higher in mature oligodendrocytes, culminating in the finding that OPCs accumulated a greater content of 2-AG than mature oligodendrocytes. Levels of anandamide (AEA) were low and did not differ between the cell stages ([@B43]). Differentiation, denoted by branching morphology and levels of MBP after 96 h, was increased by MAGL inhibitor JZL184 (1 μM), and decreased by DAGL inhibitor RHC80267 (5 μM), with exogenous 2-AG (2 μM) abolishing the effect of blocking its synthesis. Inhibition of the ERK pathway by the MEK blocker PD98059 (10 μM) abolished Western blot staining for MBP, implicating the ERK pathway in differentiation. In a CB~1~ receptor mRNA-expressing human oligodendrocyte precursor line HOG16, WIN55212-2 (1 μM, 24 h) increased MBP mRNA expression, particularly in cells treated with T3-supplemented differentiating medium ([@B120]). Collectively, these studies suggest that endogenous 2-AG in OPCs triggers the ERK pathway, leading to the maturation of arborized, MBP-producing oligodendrocytes.

The ECS and OPCs-Oligodendrocytes in Models of Disease
======================================================

The role of cannabinoids in OPCs and oligodendrocytes under stress has been evaluated in models of insults such as excitotoxicity ([@B109]; [@B12]), reactive oxygen species (ROS) toxicity ([@B97]), KCl-induced depolarization ([@B74]), as well as in models of stroke ([@B36]; [@B116],[@B117]), spinal cord injury (SCI) ([@B72]; [@B7]), and demyelination ([@B111]; [@B97]; [@B12]; [@B127]; [@B35]).

Cannabinoids and OPC-Oligodendrocytes in Cytopathology Models
-------------------------------------------------------------

The ability of cannabinoid agonists to protect neurons from excitotoxicity is well known ([@B108]; [@B51]; [@B72]; [@B123]). Likewise, ECS involvement in OPC and oligodendrocyte excitotoxicity has recently been explored ([@B109]; [@B12]). Newborn (PD5) Sprague Dawley rats received AMPA/kainate agonist bromowillardine (15 μg, IC), immediately followed by AEA (10 mg/kg, IP) ([@B109]). AEA significantly increased OPC density within the periventricular white matter lesion after 1 day, and increased MBP staining after 5 days. The ECS in excitotoxicity was also investigated in mature oligodendrocytes ([@B12]). OPCs were isolated from the cerebral cortex of newborn wildtype or CB~1~-KO Sprague-Dawley rats and differentiated with T3 minus growth factors. Oligodendrocytes were exposed to AMPA plus cyclothiazide (10 μM:100 μM) for 15 min, resulting in excessive cytosolic calcium, reactive oxygen species (ROS) production, and cell death ([@B12]). A 30-min pretreatment with CB~1~ agonist ACEA (25 nM), endocannabinoids AEA or 2-AG (1 μM), or MAGL inhibitor JZL184 (25 nM) reduced cell death ([@B12]). No protection occurred in oligodendrocytes lacking CB~1~ receptors, or pretreated with CB~2~ agonist JWH133 (25 nM) or the inhibitor of AEA metabolizing enzyme fatty acid amide hydrolase (FAAH) URB597 (10 nM -- 1 μM). These findings implicate endocannabinoids and CB~1~ receptors in improved viability of oligodendrocytes in excitotoxic conditions.

Due to their high metabolic demand, oligodendrocytes are vulnerable to elevated levels of ROS ([@B76]; [@B101]), although less so than their precursors ([@B10]). To investigate how cannabinoid agonists affect oligodendrocyte survival, precursors isolated from PD2-PD3 Sprague-Dawley rat brains were differentiated by T3 plus ciliary neurotrophic factor for 2 weeks, and exposed to a peroxynitrite generator SIN-1 (1 mM) ([@B132], [@B131]) for 2 h ([@B97]). Concurrent treatment with CB~1~/CB~2~ agonists CP55940 (1--3 μM), WIN55212-2 (10 μM), or anandamide/THC hybrid CB52 (3--10 μM), reduced cell death. CB52's mechanism included activation of CB~2~ receptors, as CB~2~ antagonist AM630 (10 μM), but not CB~1~ antagonist AM281 (10 μM) reduced its effectiveness, while CB~2~ agonists AM1241 and JWH015 partially replicated it ([@B97]).

The ability of CB~1~ agonists to inhibit depolarization-dependent calcium channels, as observed in neurons ([@B54]), was explored in oligodendrocytes ([@B74]). Precursors were isolated from optic nerve of PD12 Sprague-Dawley rats, differentiated by 2-day incubation in defined media, and exposed to KCl (50 mM, 1 min) to induce depolarization ([@B74]). Resulting calcium influx was decreased by CB~1~ agonist ACEA (1 μM) or CB~1~/CB~2~ agonists THC (3 μM), CP55940 (3 μM), AEA (3 μM) or 2-AG (3 μM), but not CB~2~ agonist JWH133 (3 μM). Oligodendrocytes from CB~1~-KO mice were less responsive to AEA and ACEA, although not completely unresponsive, suggesting other targets exist such as transient receptor potential vanilloid receptor-1 (TRPV1) ([@B100]; [@B102]), expressed in oligodendrocytes ([@B49]). In contrast, CBD (100 nM, 20--30 min) reduced oligodendrocyte viability, in part through an increase in intracellular calcium ([@B75]). CBD (1 μM, 10 min) increased oligodendrocyte production of ROS, and induced apoptosis through mitochondria-mediated activation of caspase-8 and -9 and their downstream effector caspase-3, as well as poly-(ADP ribose) polymerase-1 (PARP-1), triggered by caspase-independent mitochondrial apoptosis-induced factor (AIF) ([@B52]).

ECS and Oligodendrocytes in Stroke and Traumatic Injury
-------------------------------------------------------

Oligodendrocytes are vulnerable to ischemic conditions and their replacement via OPCs has been found to aid recovery ([@B29]; [@B129], [@B130]). The impact of the ECS was studied in adult ([@B116],[@B117]) and neonatal ([@B36]) rat models of middle cerebral artery occlusion (MCAO). In transient (2 h) MCAO ([@B116]), WIN55212-2 (9 mg/kg, IP immediately after reperfusion and daily) increased staining for penumbral OPCs and mature oligodendrocytes at 4, 7, and 14 days post ischemia (DPI), and penumbral myelin density at 14 DPI. WIN55212-2 reduced penumbral expression of caspase-3 in OPCs at 7 DPI, which correlated with reduced ERK1/2 phosphorylation. These effects were ameliorated by CB~1~ antagonist SR141716 (1 mg/kg, IV). In adult male Sprague-Dawley rats, WIN55212-2 (9 mg/kg, IV) was given within 2 h after permanent MCAO, with anoxia damage quantitated after 24 h ([@B117]). WIN55212-2 treatment increased OPC proliferation within the penumbra and ipsilateral SVZ, and decreased penumbral OPC expression of tau-1, an oligodendrocyte marker of ischemic stress ([@B28]; [@B58]). Both effects were partially due to CB~1~ receptor activation ([@B117]). In a permanent MCAO model in neonatal PD7 Wistar rats ([@B36]), WIN55212-2 (1 mg/kg, IP daily for 7 days) increased ipsilateral SVZ OPC proliferation and number of penumbral OPCs at 7 DPI. WIN55212-2 increased the number of mature penumbral oligodendrocytes at 14 and 28 DPI, and accelerated complete MBP recovery. Consistent with earlier findings ([@B46]; [@B16]), WIN55212-2 increased SVZ OPC proliferation even in the absence of ischemia. Although preclinical results appear promising for cannabinoid pharmacotherapies for anoxic demyelination, SVZ neurogenic response to stroke varies greatly between rodents and humans ([@B60]).

The endocannabinoid 2-AG has been shown to be neuroprotective after traumatic brain injury ([@B91]), and 2-AG is elevated after spinal trauma ([@B72]; [@B39]). Thus, the impact of 2-AG on oligodendrocyte survival was explored in a model of contusive SCI generated by a dropped weight in male adult Wistar rats ([@B7]). 2-AG (5 mg/kg, IP 30 min after injury) preserved myelin integrity and reduced oligodendrocyte death at the epicenter (1 day post-injury), with the same effects seen as far as 10 mm rostral of epicenter (1 and 7 days post-injury). Co-administration of both CB~1~ and CB~2~ antagonists (AM281 and AM630, respectively; 3 mg/kg, IP), but not by either alone, could reverse the effects of 2-AG. These results support the idea that improved oligodendrocyte survival and preserved white matter integrity underlie the cannabinoid-mediated improvement in SCI recovery ([@B8]).

ECS and Models of Demyelination
-------------------------------

To investigate demyelination in a mouse model of experimental autoimmune encephalomyelitis (EAE), PD49 or PD56 C57BL/6 mice received a single injection of myelin oligodendrocyte glycoprotein peptide (MOG 35-55), followed by injections of pertussis toxin on the day of MOG inoculation and again 2 days afterward ([@B12]). MAGL inhibitor JZL184 (8 mg/kg, IP daily for 3 weeks, starting on day 14 postinoculation) ameliorated the reduction in spinal cord white matter staining ([@B12]). Similar results in the EAE model were achieved by THC ([@B87]), CBD ([@B41]), cannabigerol quinone ([@B19]), and CB~2~ agonist HU308 ([@B107]). The effects of CB52 on demyelination EAE ([@B97]) showed that when initiated before symptom development (3 days) or after clinical disease onset (12 or 20 days), CB52 (2 mg/kg, IP daily) ameliorated the loss of staining for spinal cord myelin and mature oligodendrocytes at day-30. In contrast to CB52's action on cultured oligodendrocytes *in vitro* ([@B97]), both of its effects *in vivo* were blocked by CB~1~ antagonist AM281 (2 mg/kg), but not by CB~2~ antagonist AM630 (2 mg/kg).

Microglia are an integral part of demyelinating diseases' neuroimmune complex ([@B48]). In microglia, CB~1~ receptors are expressed at low levels constitutively; however, CB~2~ receptors become upregulated when microglia become activated ([@B18]). Endocannabinoids 2-AG and AEA have been shown to drive microglia toward alternative, anti-inflammatory activation state, M2, and away from classic, pro-inflammatory polarization, M1, which in turn causes microglia to upregulate its own 2-AG synthesizing enzymes ([@B77]). Because microglial 2-AG has been shown to promote OPC differentiation ([@B83]), blocking its degradation could be of use in counteracting demyelination. This has been explored in a mouse model of EAE ([@B127]), by inhibiting the 2-AG hydrolyzing microglial enzyme ABHD6 ([@B68]; [@B70]; [@B88]) with WWL70 (10 mg/kg, IP daily starting at the onset of clinical symptoms on day-11 postinoculation). WWL70 increased cerebral 2-AG at day-21, and ameliorated the loss of staining of spinal cord myelin and mature oligodendrocytes in wildtype mice on day-28 ([@B127]). These results were not seen in CB~2~-KO mice, nor when WWL70 was co-administered with CB~2~ antagonist AM630 (3 mg/kg), suggesting that microglial 2-AG accumulation is dependent upon CB~2~ receptor signaling. Co-administration with CB~1~ antagonist AM281 failed to interfere with WWL70's effects.

OPC gliogenesis in Borna Disease Virus (BDV) encephalomyelitis, generated in PD28 male Lewis rats ([@B111]), demonstrated that WIN55212-2 (1 mg/kg, IP daily for 7-days starting 1 week after virus inoculation) increased OPC proliferation in striatum, decreased apoptosis of proliferating cells, skewed precursor differentiation away from astrocytes and toward oligodendrocytes, and promoted OPC maturation. In uninfected controls, WIN55212-2 increased proliferation in both PFC and striatum.

In Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), PD28 female CJL/J mice received an intracerebral injection of the Daniel strain virus ([@B35]). When started after symptom onset at day-75, a 10-day treatment with MAGL inhibitor UCM03025 (5 mg/kg, IP) increased the spinal cord populations of both mature oligodendrocytes and OPCs, and restored MBP level to that of sham controls ([@B35]).

In the cuprizone oligodendrotoxic model ([@B12]), PD56 C57BL/6 mice were fed a cuprizone-supplemented diet (0.3%) for 3 weeks. Concurrent MAGL inhibitor JZL184 (8 mg/kg, IP daily) ameliorated cuprizone-induced reduction in corpus callosum MBP staining ([@B12]), implicating 2-AG-mediated protection.

Seizures are known to accompany demyelination in experimental models ([@B26]; [@B65]; [@B112]) as well as MS ([@B63]; [@B3]; [@B114]). The ECS promotion of OPCs ([@B111]; [@B35]) and mature oligodendrocytes ([@B97]; [@B127]; [@B35]) may counteract demyelination observed in patients with intractable epilepsy ([@B55]).

CBD and OPCs in Inflammation
----------------------------

CBD has been promoted for potential therapeutic applications ([@B27]; [@B15]; [@B57]) including anti-inflammation ([@B17]). Inflammation underlies a range of pathologies including neurodegeneration ([@B42]; [@B24]), stroke ([@B122]; [@B1]), and demyelination ([@B94]; [@B64]). To examine CBD's anti-inflammatory impact on OPC survival, cultured OPCs isolated from the forebrain of newborn Wistar rats were exposed to inflammation-related stressors ([@B78]). Treatment with CBD (1 μM) reduced: (1) caspase-3-mediated apoptosis resulting from lipopolysaccharides (LPS) and interferon-γ (IFNγ)-mediated inflammation (48 h); (2) cell death induced by endoplasmic reticulum stress instigated by tunicamycin (1 μg/ml, 24 h); and (3) cell detachment and ROS production in response to hydrogen peroxide (2 h). CBD was unable to increase OPC proliferation in culture ([@B78]), in contrast to its chronic administration in SVZ of adult Swiss mice ([@B106]). CBD did not promote apoptosis in culture, as observed in unstressed cultured oligodendrocytes ([@B75]). CBD's cellular mechanism(s) have yet to be established for OPC and oligodendrocyte function, but might counter the endocannabinoid responses at their receptors. Further, CBD may target other cell types in the neuro-immune complex, explaining differences between *in vitro* vs. *in vivo* models.

Perspectives
============

Although much has been learned about the impact of cannabinoid agonists on oligodendrocytes in health and disease, many questions remain unexplored, such as the cannabinoid impact on OPC local migration ([@B62]; [@B56]) and glutamate signaling ([@B113]), the oligodendrocyte's ability to produce myelin and provide metabolic support to axons ([@B128]; [@B103]; [@B110]). Cannabinoid agonists also comprise structurally and functional distinct ligands ([@B54]; [@B93]; [@B66]; [@B95]), and as such, it is important to characterize their pharmacological profiles in cell pathologies related to oligodendrocytes and other cell types in the neuro-immune complex. Although the impact of cannabinoid extracts on MS disease progression remains inconclusive ([@B92]; [@B96]), the outlook is optimistic ([@B6]; [@B20], [@B21]). Evidence of cannabinoid agonist effects on oligodendrocyte survival and OPC lifecycle suggests their usefulness in CNS pathologies such as demyelination ([@B94]; [@B64]), neurodegeneration ([@B34]; [@B119]), ischemia ([@B29]; [@B82]), epilepsy ([@B38]; [@B115]), and traumatic injuries to spinal cord ([@B2]; [@B67]; [@B5]) and brain ([@B9]; [@B118]).
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